Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy have?
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy has 109 citations in the OpenAlex counts ScholarIQ stores.
When was Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy published?
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy has 2022 year in the ScholarIQ index.
What is the open-access status of Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy?
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy has hybrid oa status in the ScholarIQ index.
What is the DOI of Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy?
The DOI for Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy is on the source record.
What is the PMID of Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy?
The PMID for Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy is on the source record.
What is the OpenAlex record for Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy?
The OpenAlex for Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy is on the source record.